Cat. No. 1488
Alternative Name: (trans-Cinnamoyl)-YPGKF-NH2
Biological ActivitySelective PAR4 antagonist peptide. Inhibits endostatin release and platelet aggregation induced by thrombin.
(Modifications: Tyr-1 = trans-Cinnamoyl-Tyr, Phe-5 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Hollenberg et al (2004) Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo. Br.J.Pharmacol. 143 443. PMID: 15451771.
Hollenberg and Saifeddine (2001) Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides. Can.J.Physiol.Pharmacol. 79 439. PMID: 11405248.
Ma et al (2001) Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist. Br.J.Pharmacol. 134 701. PMID: 11606309.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for tcY-NH2 include:
Carrim et al (2015) Thrombin-induced reactive oxygen species generation in platelets: A novel role for protease-activated receptor 4 and GPIbα. Br J Cancer 6 640. PMID: 26569550.
Sales et al (2015) Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis. Redox Biol 34 346. PMID: 24469043.
Do you know of a great paper that uses tcY-NH2 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: tcY-NH2, supplier, Selective, PAR4, antagonists, Receptors, Protease-Activated, proteinase-activated, Tocris Bioscience, Protease-Activated Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonistMSG 606
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonist
April 1 - 5, 2017
Washington, D.C., USA